Guidelines of German urologist on therapy of benign prostrate syndrome;Leitlinien der Deutschen urologen zur therapie des benignen prostatasyndroms (BPS)

Urologe - Ausgabe A

Volumn 42, Issue 5, 2003, Pages 722-738

  Berges, R ^b   Dreikorn, K ^b   Hofner K ^b   Jonas, U ^b   Laval, K U ^b   Madersbacher, S ^b   Michel, M C ^b   Muschter, R ^b   Oelke, M ^a   Pientka, L ^b   Tschuschke, C ^b   Tunn, U ^b   Palmtag, H ^b   Goepel, M ^b   Schalkhauser K ^b   Gockel Beining B ^b   Heidenreich, A ^b   Rubben H ^b   Thon, W ^b   Thuroff J ^b   Weidner, W ^b   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; TAMSULOSIN; TERAZOSIN;

DIAGNOSTIC APPROACH ROUTE; DRUG FORMULATION; GERMANY; HUMAN; MALE; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; PROSTATISM; REVIEW; TREATMENT PLANNING; UROLOGIC SURGERY;

EID: 0038382892     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0318-3     Document Type: Review

References (391)

1. Abrams P, Schulman CC, Vaage S (1995) Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). European Tamsulosin Study Group. Br J Urol 76/3: 325-336
2. Akan H, Basar M et al. (1998) The early effects of doxazosin on benign prostatic hyperplasia. Arch Ital Urol Androl 70/1: 41-44
3. Aliaev lu G, Vinarov AZ et al. (1999) Adrenoblockers in prophylaxis of acute urination retention after surgery. Khirurgiia 12: 43-45
4. Andersen JT, Ekman P, Wolf H et al. (1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 46/5: 631-637
5. Bales GT, Christiano AP et al. (1999) Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 54/1: 86-89
6. Barsanti JA, Finco DR et al. (2000) Effects of an extract of Serenoa repens on dogs with hyperplasia of the prostate gland. Am J Vet Res 61/8: 880-885
7. Bartsch G,Dreikom K et al. (1998) Combined sabal and urtica extract vs. finasteride in benign prostatic hyperplasia (Alken stages I to II). Comment on the contribution by J. Sokeland and J. Albrech (letter, comment). Urologe (A) 37/1: 83-85
8. Bauer HW, Casarosa C et al. (1999) Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschr Med 141/25: 62
9. Bayne CW, Donnelly F et al. (1999) Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 40/4: 232-241
10. Beduschi MC, Beduschi R et al. (1998) Alpha-blockade therapy for benign prostatic hyperplasia: from a non-selective to a more selective alpha1A-adrenergic antagonist. Urology 51/6: 861-872
11. Beique L, Por CP et al. (1998) Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?" Can Fam Physician 44: 2659-2662
12. Berges RR, Windeler J, Trampisch HJ, Senge T and the Beta-Sitosterol Study Group (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529-1532
13. Berges RR, Pientka L (1999) Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 36 (Suppl 3): 21-27
14. Berges RR, Kassen A et al. (2000) Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 85/7: 842-846
15. Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with Finasteride: meta-analysis of randomized clinical trials. Urology 48/3: 398-405
16. Boyle P, Robertson C et al. (2000) Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 55/4: 533-539
17. Boyle P, Roehrborn C, Andriole G et al. (2002) The impact of dutasteride, a novel 5α-reductase inhibitor, on the hallmarks of BPH. progression and outcomes. Eur Urol (Suppl 1) pp 107
18. Brawer MK, Adams G, Epstein H (1993) Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 2/9: 929-935
19. Bruskewitz R (1999) Management of symptomatic BPH in the US: who is treated and how? Eur Urol 36 (Suppl 3): 7-13
20. Buzelin JM, Hebert M, Blondin P (1993) Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 72/6: 922-927
21. Buzelin JM, Delauche Cavaltier MC et al. (1998) Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction (letter, comment). Br J Urol 81/4: 655-656
22. Cerrato PL (2000) Diet and herbs for BPH? RN 63/2: 63-64
23. Chacon A, Monga M (1999) Medical management of benign prostatic hyperplasia. Geriatr Nephrol Urol 9/1: 39-48
24. Chapple CR, Carter P, Christmas TJ (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74/1: 50-56
25. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F et al. (1996) Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist - A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29/2: 155-167
26. Chapple CR (1998) Pharmacotherapy for benign prostatic hyperplasia - the potential for alpha 1-adrenoceptor subtype-specific blockade. Br J Urol 81 (Suppl 1): 34-66
27. Chon JK, Borkowski A et al. (1999) Alpha1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161/6: 2002-2008
28. Christensen MM, Holme JB, Rasmussen PC (1993) Doxazosin treatment in patients with prostatic obstructions. Scand J Urol Nephrol 27: 39-44
29. Clifford GM, Farmer RD (2000) Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 38/1: 2-19
30. Cooper KL, McKiernan JM et al. (1999) Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57/1: 9-17
31. Curtis SP, Eardley I et al. (2000) Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia. Br J Clin Pharmacol 49/3: 269-273
32. Daniels DV, Gever JR et al. (1999) Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. Eur J Pharmacol 370/3: 337-343
33. Davis SR, Dalais FS et al. (1999) Phytoestrogens in health and disease. Recent Prog Horm Res 54: 185-210
34. de Mey C (1998) Cardiovascular effects of alphablockers for the treatment of symptomatic BPH. Eur Urol 34 (Suppl 2): 18-28; discussion 47
35. de Mey C (1999) Alpha(1)-blockers for BPH: are there differences? Eur Urol 36 (Suppl 3): 52-63
36. Debruyne FM, Van der Poel HG (1999) Clinical experience in Europe with uroselective alpha1-antagonists. Eur Urol 36 (Suppl 1): 54-58; discussion 65
37. Debruyne FM, Jardin A et al. (1998) Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 34/3: 169-175
38. Di Silverio F, Monti S et al. (1998) Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37/2: 77-83
39. Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36/1: 1-13
40. Elhilali MM, Ramsey EW, Barkin J et al. (1996) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 47/3: 335-342
41. Eri LM, Tveter KJ (1995) Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 154/3: 923-934
42. Fawzy A, Braun K, Lewis GP et al. (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154/1: 105-109
43. Finasteride Study Group (1993) Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291-299
44. Fitzpatrick JM (1999) Phytotherapy for treatment of benign prostatic hyperplasia: case not proven. Urology 53/3: 462-464
45. Foley SJ, Soloman LZ, Wedderburn AW (2000) A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 163/2: 496-498
46. Fourcade RO (2000) Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group, Prog Urol 10/2: 246-253
47. Gerber GS (2000) What is saw palmetto used for, and does it interact with any medications? Health News 6/6: 10
48. Gerber GS (2000) Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol 163/5: 1408-1412
49. Gerber GS, Zagaja GP et al. (1998) Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 51/6: 1003-1007
50. Gillenwater JY, Conn RL, Chrysant SG et al. (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled dose-response multicenter study. J Urol 154/1: 110-115
51. Gillenwater JY (1998) Comment on the appropriateness of the prostate publishing a trial comparing permixon to finasteride without a placebo control group. Prostate 37/3: 194
52. Goepel M, Hecker U et al. (1999) Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 38/3: 208-215
53. Gormley GJ, Stoner E, Bruskewitz RC et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327/17: 1185-1191
54. Guthrie RM, Siegel RL (1999) A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther 21/10: 1732-1748
55. Hedlund H, Hedlund P (1999) Treatment of benign prostatic enlargement with alpha-blockers: an updated review. Scand J Urol Nephrol (Suppl) 203: 9-13
56. Hofner K,Claes H et al. (1999) Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36/4: 335-341
57. Holme JB, Christensen MM, Rasmussen PC et al. (1994) 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol and Nephrol 28: 77-82
58. Holtgrewe HL (1998) Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51 (4A Suppl): 1-7
59. Horiuchi K, Tsuboi N et al. (1999) The short-term effects of tamsulosin in Japanese men with benign prostatic hyperplasia. Nippon Ika Daigaku Zasshi 66/6: 382-387
60. Italian Alfuzosin Cooperative Group (1995) Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. Eur Urol 27: 128-134
61. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P (1993) Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. Br J Urol 72: 615-620
62. Jardin A, Bensodoun H, Delauche-Cavallier MC, Attali P (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 337: 1457-1461
63. Jolliet P, Bourin M (1998) Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach. Therapie 53/1: 61-66
64. Jonas A, Rosenblat G et al. (1998) Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5alpha reductase activity, aromatase activity and lipid peroxidation. Urol Res 26/4: 265-270
65. Jonler M, Wasson JH, Reda DJ, Bruskewitz RC (1994) Analysis of watchful waiting studies. Progress in Clinical and Biological Research. In: Kurth K, Newling DWW (eds) Benign prostatic hyperplasia. New York, 386: 291-302
66. Kassen A, Berges R et al. (2000) Effect of beta-sitosterol on transforming growth factor-beta-1 expression and translocation protein kinase C alpha in human prostate stromal cells in vitro. Eur Urol 37/6: 735-741
67. Kawachi I, Barry MJ, Giovannucci E et al. (1996) The impact of different therapies on symptoms of benign prostatic hyperplasia: a prospective study. Clin Ther 18/6: 1118-1127
68. Kirby RS (1999) Clinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol 36 (Suppl 1): 48-53;discussion 65
69. Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind, clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 80/3: 427-432
70. Kondas J, Philipp V et al. (1997) Sabal serrulata extract in the management of symptoms of prostatic hypertrophy. Orv Hetil 138/7: 419-421
71. Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60/16: 4550-4555
72. Labasky RF (1996) Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement - Comment. J Urol 156: 1034
73. Langer SZ (1999) History and nomenclature of alpha1-adrenoceptors. Eur Urol 36 (Suppl 1): 2-6
74. Lee M (2000) Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 34/2: 188-199
75. Lepor H (1998) Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 51/6: 901-906
76. Lepor H (1998) Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51/6: 892-900
77. Lepor H, Jones K (2000) The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 163/4: 1134-1137
78. Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148/5: 1467-1474
79. Lepor H, Williford WO, Barry MJ et al. (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335/8: 533-539
80. Levin RM, Das AK (2000) A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 28/3: 201-209
81. Lloyd SN, Buckley JF, Chilton CP et al. (1992) Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 70: 17-21
82. Lowe FC, Fagelman E (1999) Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology S3/4: 671-678
83. Lowe FC, Dreikorn K et al. (1998) Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37/3: 187-193
84. Lowenthal DT, Flannery M et al. (1998) Benign prostatic hyperplasia: maximizing treatment with alpha blockers. Geriatrics 53 Suppl 2: S4-28
85. Lukacs B, McCarthy C, Grange JC and the QOL BPH Study Group in General Practice (1993) Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results ofa cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. Eur Urol 24: 34-40
86. Lukacs B (1999) Management of symptomatic BPH in France: who is treated and how? Eur Urol 36 (Suppl 3): 14-20
87. Lukacs B, Grange JC et al. (1998) Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice. Eur Urol 33 (Suppl 2): 28-33
88. Lukacs B, Grange JC et al. (1999) Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice. Prog Urol 9/2: 271-280
89. Lukacs B, Grange JC et al. (2000) History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol 37/2: 183-190
90. Lukacs B, Grange JC et al. (2000) One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IP5S and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology 55/4: 540-546
91. MacDonald R, Ishani A et al. (2000) A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85/7: 836-841
92. Man in't Veld AJ (1998) Symptomatic BPH and hypertension: does comorbidity affect quality of life? Eur Urol 34 (Suppl 2): 29-36; discussion 47
93. Mann RD, Biswas P et al. (2000) The pharmacovigilance of tamsulosin: event data on 12484 patients. BJU Int 85/4: 446-450
94. Marks LS, Tyler VE (1999) Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia (editorial). Urology 53/3: 457-461
95. Marks LS, Partin AW et al. (2000) Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 163/5: 1451-1456
96. Martelli A, Pacifico P, Casadei G (1993) Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Eur Urol 24: 28-33
97. Martin DJ (1999) Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol 36 (Suppl 1): 35-41; discussion 65
98. Maruenda J, Bhatnagar V et al. (1999) Hypertension in the elderly with coexisting benign prostatic hyperplasia. Urology 53(3 Suppl 3a): 7-12;discussion 12-13, 41-42
99. Maruyama K, Nakamura T et al. (1998) Tamsulosin: assessment of affinity of 3H-prazosin bindings to two alpha1-adrenoceptor subtypes (alpha1H and alpha1L) in bovine prostate and rat heart and brain. Gen Pharmacol 31/4: 597-600
100. McConnell J, Bruskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338/9: 557-563
101. McKinney DE (1999) Saw palmetto for benign prostatic hyperplasia. Jama 281/18: 1999
102. McNeill SA, Daruwala PD et al. (1999) Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int 84/6: 622-627
103. McPartland JM, Pruitt PL (2000) Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc 100/2: 89-96
104. Michel MC, Bressel HU et al. (1998) Tamsulosin: real life clinical experience in 19,365 patients. Eur Urol 34 (Suppl 2): 37-45
105. Michel MC, Mehlburger L et al. (1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? (Published erratum appears in J Urol (1998) 160: 2164). J Urol 160: 784-791
106. Mimata H, Nomura Y et al. (1999) Prediction of alphablocker response in men with benign prostatic hyperplasia by magnetic resonance imaging. Urology 54/5: 829-833
107. Muramatsu I, Taniguchi T et al. (1998) Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin. Jpn J Pharmacol 78/3: 331-335
108. Muschter R, Hofstetter A (1999) Conservative treatment of the BPH syndrome. Diagnosis and drug therapy. Fortschr Med 117/15: 18-20
109. Na YJ, Guo YL et al. (1998) Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med 29/5-6: 289-304
110. Nacey JN, Meffan PJ, Delahunt B (1995) The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. Aust N Z J 5urg 65/1: 35-39
111. Narayan P (1998) Tamsulosin: the United States trials. Geriatrics 53 (Suppl 2): 529-532
112. Narayan P, Tewari A (1998) A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 160/5: 1701-1706
113. Neal DE (1997) Watchful waiting or drug therapy for benign prostatic hyperplasia. Lancet 350: 305-356
114. Nickel JC, Fradet Y, Boake RC et al. (1996) Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). CMAJ 15/9: 1251-1259
115. Nickel JC (1998) Long-term implications of medical therapy on benign prostatic hyperplasia end points. Urology 51(4A Suppl): 50-57
116. Okada H, Kamidono S et al. (2000) A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int. 85/6: 676-681
117. Palin MF, Faguy et al. M (1998) Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity. Endocrine 9/1: 65-69
118. Paubert-Braquet M,Cousse H et al. (1998) Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 33/3: 340-347
119. Roehrborn CG, Oesterling JE, Auerbach S et al. (1996) The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment ofmen with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 47/2: 159-168
120. Roehrborn C, Andriole G, Boyle P, Höfner K (2002) Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume. Eur Urol (Suppl 1), pp 107
121. Sall M, Bruskewitz R (1996) Treatment of benign prostatic hyperplasia: surgery, medical therapy, or watchful waiting. Compr Ther 22/9: 554-558
122. Sanchez-Chapado M, Guil M et al. (2000) Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. Eur Urol 37/4: 421-427
123. Schilcher H (1999) Is there a rational therapy for symptomatic treatment of benign prostatic hyperplasia with phytogenic drugs? Illustrated with the example of the prostate agent from Serenoa repens (Sabal fructus). Wien Med Wochenschr 149/8-10: 236-240
124. Schulman CC, Cortvriend J, Jonas U et al. (1996) Tamsulosin, the first prostate-selective alpha(1A)-adrenoceptor antagonist - Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29/2: 145-154
125. Schulman CC, de Sy W, Vandendries M, Tomas M, Santoni JP (1994) Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. Acta Urologica Belgica 62/4: 15-21
126. Schulman CC, Cortvriend J et al. (1999) Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 36/6: 609-620
127. Segars LW (1999) Saw palmetto extracts for benign prostatic hyperplasia. J Fam Pract 48/2: 88-89
128. Sökeland J, Albrecht J (1997) Kombination aus Sabalund Urticaextrakt versus Finasterid bei BPH (Stadium I-III nach Alken). Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe (A) 36: 327-333
129. Sökeland J, Albrecht J. (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study (see comments). Urologe (A) 36/4: 327-333
130. Speakman MJ (1999) Who should be treated and how? Evidence-based medicine in symptomatic BPH. Eur Urol 36 (Suppl 3): 40-51
131. Stepanov VN, Siniakova LA et al. (1999) Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 16/5: 231-241
132. Stoner E (1994) Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. Arch of Intern Med 154: 83-88
133. Stoner E (1994) Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43: 284-294
134. Suzuki Y, N Moriyama N et al. (2000) Distribution of alpha1L-adrenoceptors in canine prostate: characterization by quantitative autoradiography. J Pharm Pharmacol 52/6: 653-657
135. Swoboda, H, Kopp B (1999) Serenoa repens - the saw palmetto of dwarf palm. Wien Med Wochenschr 149/8-10: 235
136. Tewari A, Narayan P (1999) Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Urology 53(3 Suppl 3a): 14-20; discussion 41-42
137. The Finasteride Study Group (1993) Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291-299
138. The Italian Alfuzosin Cooperative Group (1995) Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. Eur Urol 27: 128-134
139. Tkachuk VN, Al'-Shukri S et al. (1998) Combined use of 5 alpha-reductase inhibitors and alpha-I adrenergic receptor blockers in patients with benign prostatic hyperplasia. Urol Nefrol (Mosk) 3: 5-8
140. Tsujii T (2000) Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia Int J Urol 7/6: 199-205
141. Tubaro A, Montanari E (1999) Management of symptomatic BPH in Italy: who is treated and how? Eur Urol 36 (Suppl 3): 28-32
142. Van Coppenolle F, Le Bourhis X et al. (2000) Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 43/1: 49-58
143. van Kerrebroeck P, Jardin A et al. (2000) Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 37/3: 306-313
144. Vela Navarrete R, Gabriel R et al. (2000) Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin. Actas Urol Esp 24/2: 120-130
145. Wasson JH, Reda DJ, Bruskewitz RC et al. (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 332/2: 75-79
146. Wilt TJ, Ishani A et al. (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review (published erratum appears in JAMA (1999) 281/6: 515). Jama 280/18: 1604-1609
147. Wilt T, Ishani A et al. (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2
148. Wilt T, Ishant A et al. (2000) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2
149. Wilt T, Mac Donald R et al. (2000) Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev 2
150. Witjes WP, de Wildt MJ, Rosier PF et al. (1996) Variability of clinical and pressure-flow study variables after 6 month of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol 156: 1026-1034
151. Wyllie MG (1999) alpha1-adrenoceptor selectivity: the North American experience. Eur Urol 36 (Suppl 1): 59-63; discussion 65
152. Yu HJ, Chiu TY, Lai MK (1995) Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. J Formos Med Assoc 94/1-2: 37-41
153. Al Shukri SH, Deschaseaux P, Kuzmin IV, Amidy RE (2000) Early urodynamic effects of the lipido-sterolic extract of Serenea Repens (Permixon(r)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 3/3: 195-199
154. Altwein J, Aumüller G, Berges R et al. (1999) Leitlinien der Deutschen Urologen zur Therapie des BPH-Syndroms. Urologe (A) 38: 529-536
155. Andro MC, Riffaud JP (1995) Pygeum Africanum extract for the treatment of patients with benign prostatic hyperplasia: Review of 25 years of published experience. Curr Therap Res 56: 796-817
156. Barlet A, Albrecht J, Aubert A et al. (1990) Efficacy of Pygeum africanum extract in the treatment of micturitional disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters: A multicentre, placebo-controlled double-blind trial. Wien Klin Wochenschr 102: 667-673
157. Bayne CW, Donelly F, Chapman K et al. (1998) A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5-alpha-reductase. J Clin Endocrinol Metab 83: 206-213
158. (r)): a 5-alpha-reductase types I and II inhibitor-new evidence in a co-culture model of BPH. Prostate 40: 232-241
159. Berges RR, Kassen A, Senge T (2000) Treatment of symptomatic benign prostatic hyperplasia with β-sitosterol: an 18-month follow-up. BJU Int. 85: 842-846
160. Boyle P, Gould AI, Roehrborn G (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomised clinical trials. Urology 48: 398-405
161. (r) in the treatment of symptomatic benign prostatic hyperplasia. Urology 55: 533-539
162. Breu W, Hagenlocher M, Redl K et al (1992) Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid gewonnenen Sabalfrucht-Extraktes. In-vitro-Hemmung des Cyclooxygenase- und 5-Lipoxygenase-Metabolismus, Drug Res 42: 547-551
163. Breza J, Dziurny O, Borowka A et al (1998) Efficacy and acceptability of Tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): A multicentre trial in Central Europe, Curr Med Res Opin 3: 127-139
164. Buck AC (1996) Phytotherapy for the prostate. Brit J Urol 78: 325-336
165. Buttyan R et al. (1992) Early molecular response to rabbit bladder outlet obstruction. Neurol Urodyn 11: 225-238
166. Carbin BE, Larsson B, Lindahl O (1990) Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 66: 639-641
167. Chapple CR (1999) Introduction and concluding remarks. Eur Urol 36 (Suppl 3): 1-6
168. Chatelain C, Autet W, Brackmann F (1999) Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: A randomised, double-blind study with long term open label extension. Urology 54: 473-478
169. Chen MW, Levin RM, Horan P et al. (1999) Effects of unilateral ischemia on the contractile response of the bladder. Protective effect of Tadenan (Pygeum africanum extract). Mol Urol 3/1: 5-10
170. Dathe G, Schmid H (1987) Phytotherapie der benignen Prostatahyperplasie: Doppelblindstudie mit Extractum Radicis Urticae (ERU). Urologe B 27: 233-226
171. (r)). J Urol 155 (Suppl): 572 A
172. th International Consultation of Benign Prostatic Hyperplasia (BPH). Plymbridge, Plymouth, pp 669-684
173. (r) in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 9: 291-297
174. Di Silverio F, D'Eramo G, Lubrano C et al. (1992) Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 21: 309-314
175. Dreikorn K (2000) Phytotherapeutic agents in the treatment of benign prostatic hyperplasia. Curr Urol Rep 1/2: 103-109
176. Dreikom K, Richter R (1989) Conservative nonhormonal treatment of patients with benign prostatic hyperplasia, New Developements in Biosciences 5: 109-121
177. Dreikorn K, Schönhöfer PS (1995) Stellenwert von Phytotherapeutika bei der Behandlung der benignen Prostatahyperplasie (BPH), Urologe (A) 34: 119-129
178. th International Consulation on Benign Prostatic Hyperplasia (BPH) 1997. Plymbridge, Plymouth, pp 633-659
179. th International Consultation on Benign Prostatic Hyperplasia
180. Dutkiewicz S (1996) Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol 28/1: 49-53
181. Engelmann U, Boos G, Kres H (1996) Therapie der benignen Prostatahyperplasie mit Bazoton Liquidum. Urologe B 36: 287-291
182. Ernst E (1998) Harmless herbs? A review of the recent literature, Am J Med 104: 170-178
183. Fitzpatrick JM (1998) Phytotherapy for treatment of benign prostatic hyperplasia: Case not proven, Urology 53: 462-464
184. Fitzpatrick JM, Lynch TH (1995) Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 22/2: 407-412
185. Fitzpatrick JM, Lynch TH (1996) Phytotherapeutic agents. In: Kirby R, McConnell JD, Fitzpatrick JM et al. (eds) Textbook of Benign Prostatic Hyperplasia. Isis Medical Media, Oxford, pp 331-337
186. rd International Consulation on benign prostatic hyperplasia (BPH), Monaco, June 26-28 1995 S. C. I., pp 489-494
187. nd International Consultation on benign prostatic hyperplasia (BPH), Paris, June 26.-27. 1991, S. C. I., pp 195-199
188. nd International Consultation on benign prostatic hyperplasia (BPH), Paris, June 27.-30. 1993, S. C. I., pp 445-450
189. Friedland DJ, GO AS, Davoren JB et al. (1998) Evidence-based Medicine: A Frame Work for Clinical Practice. Appleton & Lange, Stamford
190. Gerber GS, Zagaja GP, Bales GT et al. (1998) Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 51/6: 1003-1007
191. Goepel M, Dinh L, Mitchell A et al. (2001) Do Saw palmetto extracts block human α1-adrenoceptor subtypes in vivo? Prostate 46: 226-232
192. Goepel M, Hecker U, Krege S, Rübben H, Michel MC (1999) Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 38: 208-215
193. Habib FK, Ross M, Bayne CW et al. (1998) The localisation and expression of 5-alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures. J Endocrinol 156/3: 509-517
194. Habib FK, Ross M, Lewenstein A et al. (1995) The identification of a prostate inhibitory substance in a pollen extract. Prostate 26: 133-139
195. th Int. Cons. on BPH, Paris (Abstr) 77
196. Hass MA, Nowak DM, Leonova E et al. (1999) Identification of components of Prunus africana extract that inhibit lipid peroxidation, Phytomedicine 6/5: 379-388
197. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K (2001) Myristoleic acid, a cytotoxic component in the extract from Serenoa Repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 47: 59-65
198. Ishani A, MacDonald R, Nelson D, Rutks I, Wilt TJ (2000) Pygeum Africanum for the treatment of patients with benign prostatic hyperplasia: A systematic review and quantitative meta-analysis. Am J Med 109/8: 654-664
199. Jonas A, Rosenblut G, Krapf D et al. (1998) Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5-alpha-reductase activity, aromatase activity and lipid peroxidation. Urol Res 26: 265-270
200. th 2001, Anaheim, USA
201. Kurtzweil P (1999) An FDA guide to dietary supplements. US Food and Drug Administration http://vm.cfsan.fda.gov/~dms/fdsupp.html
202. LeLorier J, Grégoire G, Benhaddad A et al. (1997) Discrepancies between meta-analyses and subsequent large randomised, controlled trials, N Engl J Med 337: 536-542
203. Lepor H, Williford WO, Barry MJ et al. (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia, N Engl J Med 335/8: 533-539
204. (r) on bladder function secondary to partial outlet obstruction. J Urol 155/4: 1466-1470
205. (r) pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 156/6: 2084-2088
206. (r). J Urol 157 (Suppl 4): 172
207. Lowe FC, Ku JC (1996) Phytotherapy in treatment of benign prostatic hyperplasia; a critical review. Urology 48/1: 12-20
208. Lowe FC, Fagelman E (1998) Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 8: 27-29
209. Lowe FC, Fagelman E (1999) Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 53/4: 671-678
210. Lowe FC, Dreikorn K, Borkowski A et al. (1998) Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37: 187-193
211. MacDonald R, Ishani A, Rutks I et al. (2000) Asystematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 85: 836-841
212. Marks LS, Tyler VE (1999) Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology 53/3: 457-461
213. Marks LS, Hess DL, Dorey FJ et al. (2001) Tissue effects of Saw palmetto and finasteride: Use of biopsy cores for in situ quantification of prostatic androgens. Urology 57/5: 999-1005
214. Metzker M, Kieser M, Hölscher U (1996) Wirksamkeit eines Sabal-Urtica-Kombinationspräparates bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36: 292-300
215. (r) (lipid sterolic extract of serenoa repens) and some of its components inhibit b-FGF- and EGF-induced proliferation of human prostate organotypic cell lines, J Urol 157 (Suppl 4): 138, Abstr 541
216. (r)) and its major components on basic fibroblast growth factor-induced proliferation of culutures o human prostatic biopsies. Eur Urol 33: 340-347
217. r)): A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9/5: 379-395
218. (r)), a S-α reductase inhibitor and various commercial plant extracts in in vitro and in vivo S-α reductase inhibition. Prostate 22/1: 43-51
219. Speakman MJ (1999) Who should be treated and how? Evidence based medicine in symptomatic BPH. Eur Urol 36 (Suppl 3): 40-51
220. (r)) in the inhibition of S-alpha reductase in healthy male volunteers. Eur Urol 26/3: 247-252
221. (r) on apoptosis and proliferation in the prostate of patients with BPH. J Urol 161: 362
222. Vontobel HP, Herzog R, Rutishauser GH (1985) Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie. Urologe (A) 24: 49-51
223. Wilt TJ (2000) Phytotherapy. In: Chapple CR, McConnell JD, Tubaro A (eds) Benign Prostatic Hyperplasia. Martin Dunitz, London, pp 39-63
224. Wilt TJ, Ishani A, Stark G et al. (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280: 1604-1609
225. Wilt TJ, McDonald R, Ishani A (1999) β-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 83: 976-983
226. Wilt TJ, Ishani A, Rutks I, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3/4A: 459-472
227. Yablonsky F, Riffaud JP (1995) Pygeum Africanum for the treatment of patients with BPH: a review of 25 years of published experience. Curr Therap Res 56: 796-817
228. Aagaard J, Jonler M, Fuglsig S et al. (1994) Total transurethral resection versus minimal transurethral resection of the prostate - A 10-year follow-up study of urinary symptoms, uroflowmetry and residual volume. Br J Urol 74: 333-336
229. Altwein JE (1994)The indications for surgical treatment of BPH. Prog Clin Biol Res 386: 357-367
230. Altwein JE (1998) Obstructive benign prostatic hyperplasia: therapeutical aspects. Eur Urol 34 (Suppl 1): 31-37
231. Ansari MZ, Costello AJ et al. (1998) Adverse events after prostatectomy in Victorian public hospitals. Aust N Z J Surg 68/12: 830-836
232. Ansari MZ, Costello AJ et al. (2000) In-hospital mortality after transurethral resection of the prostate in Victorian public hospitals. Aust N Z J Surg 70/3: 204-208
233. Anson K, Nawrocki J, Buckley J et al. (1995) A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 46: 305-310
234. Benson RC (1995) Editorial comment: transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 45: 767
235. Blute ML, Tomera KM, Hellerstein DK et al. (1993) Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J Urol 150: 1591-1596
236. Bryan NP, Byrne L et al. (1999) A pilot study for a randomized controlled trial comparing the efficacy, safety and cost-effectiveness of surgical treatments of the prostate. BJU Int. 83/3: 249-253
237. Caballero Alcantara J, Marchal Escalona C et al. (1999) Economic impact of complications after transurethral resection of the prostate on its cost throughout the process. Actas Urol Esp 23/3: 232-246
238. Campo B, Bergamaschi F, Corrada P, Ordesi G (1997) Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 49: 847-850
239. Carter A, Sells H et al. (1999) A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up. BJU Int. 83/3: 254-259
240. Cattolica EV, Sidney S, Sadler MC (1997) The safety of transurethral prostatectomy: a cohort study of mortality in 9,416 men. J Urol 158: 102-104
241. Cerruti G, Tani F (1994) TUIP for infravesically obstructed BPH patients: a review of 300 cases. Arch Esp Urol 47/9: 911-914
242. Cetinel B, Turan T, Talat Z et al. (1994) Update evaluation of benign prostatic hyperplasia: when should we offer prostatectomy? Br J Urol 74: 566-571
243. Cetinkaya M, Ulusoy E, Adsan O et al. (1996) Comparative early results of transurethral electroresection and transurethral electrovaporization in benign prostatic hyperplasia. Br J Urol 78: 901-903
244. Chander J, Gupta U et al. (2000) Safety and efficacy of transurethral resection of the prostate under sedoanalgesia. BJU Int. 86/3: 220-222
245. Chen SS, Hong JG et al. (2000) The correlation between clinical outcome and residual prostatic weight ratio after transurethral resection of the prostate for benign prostatic hyperplasia. BJU Int. 85/1: 79-82
246. Cherrie RJ, Young RA, Cattolica EV (1997) The safety of overnight hospitalization for transurethral prostatectomy: a prospective study of 200 patients. J Urol 157/2: 531-533
247. Chiou RK, Binard JE, Ebersole ME et al. (1994) Randomized comparison of balloon dilation and transurethral incision for treatment of symptomatic benign prostatic hyperplasia. J Endourol 8/3: 221-224
248. Chow VD, Sullivan LD et al. (1998) Transurethral electrovaporization of the prostate versus transurethral prostatic resection: a comparison of postoperative hemorrhage. Urology 51/2: 251-253
249. Costello AJ, Crowe HR, Jackson T, Street A (1995) A randomised single institution study comparing laser prostatectomy and transurethral resection of the prostate. Ann Acad Med Singapore 24/5: 700-704
250. Cowles RS 3rd, Kabalin JN, Childs S et al. (1995) A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 46/2: 155-160
251. Crowley AR, Horowitz M, Chan E, Macchia RJ (1995) Transurethral resection of the prostate versus open prostatectomy: long-term mortality comparison. Journal of Urology 153: 695-697
252. Daehlin L, Frugard J (1999) Three-year follow-up after transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia using the PRIMUS U + R device. Scand J Urol Nephrol 33: 217-221
253. Dahlstrand C, Walden M, Geirsson G, Pettersson S (1995) Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 76: 614-618
254. D'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ (1997) High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of follow-up. J Urol 158: 120-125
255. De Geeter P, Persson C, Lindenborn H, Scherer M (1997) MRI-Imaging: an efficient method to compare different, "TUMT"-devices? J Endourol 11 (Suppl 1): 156
256. De la Rosette JJ, Froeling FM, Debruyne FM (1993) Clinical results with microwave thermotherapy of benign prostatic hyperplasia. Eur Urol 23 Suppl 1: 68-71
257. De la Rosette JJ, De Wildt MJ, Höfner K et al. (1996) High energy thermotherapy in the treatment in benign prostatic hyperplasia: results of the European benign prostatic hyperplasia study group. J Urol 156: 97-102
258. De la Rosette JJ, De Wildt MJ, Höfner K et al. (1996) Pressure-flow-study analysis in patients treated with high energy thermotherapy. J Urol 156: 1428-1433
259. De Wildt MJ, de la Rosette JJ, Debruyne FM (1994) Retreatment rate after surgical and non-surgical treatments. Prog Clin Biol Res 386: 597-613
260. De Wildt MJ, Tubaro A, Höfner K et al. (1995) Responders and nonresponders to transurethral microwave thermotherapy: a multicenter retrospective analysis. J Urol 154: 1775-1778
261. De Wildt MJ, d'Ancona FCH, Hubregste M et al. (1996) Three-year follow up of patients treated with lower energy microwave thermotherapy. J Urol 156: 1959-1963
262. De Wildt MJ, Debruyne FM, de la Rosette JJ (1996) High energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 48: 416-423
263. De Wildt MJ, Hubregtse M, Ogden C et al. (1996) A 12-month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol 77: 221-227
264. Devonec M, Tomera K, Perrin P (1993) Review: transurethral microwave thermotherapy in benign prostatic hyperplasia. J Endourol 7/3 255-259
265. Devonec M, Carter SS, Tubaro A et al. (1995) Microwave therapy. Curr Opin Urol 5: 3-9
266. Dimitri M (1999) TURP with the new superpulsed radiofrequency energy: More than a gold standard. Eur Urol 36/4: 331-334
267. DiSilverio F, D'Eramo G, Flammia GP et al. (1996) Comparative effects of transurethral incision (TUIP) and TUIP plus LHRH analogue in the treatment of benign prostate hyperplasia. J Urol 102: 111-116
268. Djavan B, Madersbacher S et al. (1999) Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia. Tech Urol 5/1: 12-20
269. Doll HA, Black NA, McPherson K (1994) Transurethral resection of the prostate for benign prostatic hypertrophy: factors associated with a successful outcome at 1 year. Br J Urol 73/6: 669-680
270. Donovan JL, Brookes ST et al. (1999) The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-'BPH'study. BJU Int. 83/3: 243-248
271. Donovan JL, Peters TJ et al. (2000) A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. J Urol 164/1: 65-70
272. Ekengren J, Haendler L et al. (2000) Clinical outcome 1 year after transurethral vaporization and resection of the prostate. Urology 55/2: 231-235
273. ElMalik EM, Ibrahim AI et al. (2000) Risk factors in prostatectomy bleeding: preoperative urinary infection is the only reversible factor. Eur Urol 37/2: 199-204
274. Emberton M, Black N, Blandy JP et al. (1995) The effectiveness of prostatectomy in reducing symptoms and improving the quality of life in 5131 men. J Urol 153: 317A
275. Emberton M, Neal DE, Black Fordham M et al. (1996) The effect of prostatectomy on symptom severity and quality of life. Br J Urol 77/2: 233-247
276. Erdagi U, Akman RY et al. (1999) Transurethral electrovaporization of the prostate versus transurethral resection of the prostate: a prospective randomized study. Arch Ital Urol Androl 71/3: 125-130
277. Floratos DL, Kiemeney LA, Rossi C et al. (2001) Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 165/5: 1533-1538
278. Foley SJ, Kennedy JE (1999) Haematuria and clot retention after transurethral resection of the prostate: a pilot study. BJU Int. 83/6: 738
279. Fourcade RO, Vallancien G (2000) Morbidity of endoscopic prostatic resection: 3-month prospective study. Prog Urol 10/1: 48-52
280. Fuglsig S, Aagaard J, Jonler M, Olesen S, Norgaard JP (1994) Survival after transurethral resection of the prostate: a 10-year followup. J Urol 151/3: 637-639
281. Gallucci M, Puppo P et al. (1998) Transurethral electrovaporization of the prostate vs. Transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. Eur Urol 33/4: 359-364
282. Goldfarb B, Bartkiw T, Trachtenberg J (1995) Microwave therapy of benign prostatic hyperplasia. Urol Clin North Am 22: 431-439
283. Gotoh M, Okamura K et al. (1999) A randomized comparative study of the Bandloop versus the standard loop for transurethral resection of the prostate. J Urol 162/5: 1645-1647
284. Gray M, Allensworth D (1999) Electrovaporization of the prostate: initial experiences and nursing management. Urol Nurs 19/1: 25-31
285. Gujral S, Abrams P, Donovan JL et al. (2000) A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention. The ClasP study. J Urol 164/1: 59-64
286. Haab F, Yamaguchi R, Leach GE (1996) Post-prostatectomy incontinence. Urol Clin North Am 23: 447-458
287. Hagerty JA, Ginsberg PC et al. (2000) Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 55/5: 684-689
288. Hahn RG, Nilsson A, Farahmand BY, Persson PG (1997) Blood haemoglobin and the long-term incidence of acute myocardial infarction after transurethral resection of the prostate. Eur Urol 31/2: 199-203
289. Hammadeh MY, Madaan S et al. (1998) Two-year follow-up of a prospective randomised trial of electrovaporization versus resection of prostate. Eur Urol 34/3: 188-192
290. Hanbury DC, Sethia KK (1995) Erectile function following transurethrale prostatectomy. Br J Urol 75: 12-13
291. Hargreave TB, Heynes CF, Kendrick SW, Whyte B, Clarke JA (1996) Mortality after transurethral and open prostatectomy in Scotland. Br J Urol 77: 4: 547-553
292. Haupt G, Pannek J, Benkert S et al. (1997) Transurethral resection of the prostate with microprocessor controlled electrosurgical unit. J Urol 158: 497-501
293. Höfner K (2000) Transurethrale Mikrowellenthermotherapie (TUMT). In: Höfner K, Stief CG, Jonas U (Hrsg) Benigne Prostatahyperplasie - ein Leiffaden für die Praxis. Springer, Berlin Heidelberg New York Tokio, S 323-353
294. Höfner K, Krah H, Kuczyk M, Tan HK, Jonas U (1995) Changes in outflow obstruction following transurethral microwave thermotherapy, in: Marberger (Hrsg.): Application of newer forms of energy in urology. Isis Medical Media Ltd, Oxford,. 41-49
295. Höfner K, Gonnermann O, Oelke M, Kuczyk M, Jonas U (1997) Transurethral microwave thermotherapy and laser treatment. Curr Opin Urol 7: 169-179
296. Holman CD, Wisniewski ZS et al. (1999) Mortality and prostate cancer risk in 19,598 men after surgery for benign prostatic hyperplasia. BJU Int 84/1: 37-42
297. Holtgrewe HL (1995) Transurethral prostatectomy. Urol Clin North Am 22/2: 357-368
298. Horninger W, Unterlechner H, Strasser H, Bartsch G (1996) Transurethral prostatectomy: Mortality and morbidity. Prostate 28/3: 195-200
299. Ibrahim AI, El-Malik E, Ghali AM, Murad N, Saad M (1995) Effect of age, comorbidity and type of surgery on perioperative complications and mortality of prostatectomy. Br J Urol 76/3: 341-345
300. Ilkjaer LB, Lund L et al. (1998) Outcome of transurethral prostatectomy in men over 80 years. Scand J Urol Nephrol 32/4: 270-272
301. Irani J, Bon D, Fournier E, Dore B, Aubert J (1996) Patient acceptability of transurethral incision of the prostate under local anaesthesia. Br J Urol 78: 904-906
302. Jahnson S, Dalen M et al. (1998)Transurethral incision versus resection of the prostate for small to medium benign prostatic hyperplasia. Br J Urol 81/2: 276-281
303. Jepsen JV, Bruskewitz RC (1998) Recent developments in the surgical management of benign prostatic hyperplasia. Urology 51(4A Suppl): 23-31
304. Jonler M, Bruskewitz RC (1994) Transurethral incision of the prostate for the treatment of benign prostatic hyperplasia. Semin Urol 12/3: 156-160
305. Jorgensen JB, Seidelin C, Petersen F, Frimodt-Moller C (1997) Does old age contraindicate TURP. Eur Urol 31: 281-285
306. Kabalin JN, Gill HS, Bite G, Wolfe V (1995) Comparative study of laser versus electrocautery prostaticresection: 18-month followup with complex urodynamic assessment. J Urol 153: 94-98
307. Kageyama S, Watanabe T et al. (2000) Can persisting detrusor hyperreflexia be predicted after transurethral prostatectomy for benign prostatic hypertrophy? Neurourol Urodyn 19/3: 233-240
308. Kaplan SA, Laor E et al. (1998) Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: a blinded, prospective comparative study with 1-year followup. J Urol 159/2: 454-458
309. Keijzers GB, Francisca EA, D'Ancona FC et al. (1998) Long-term results of lower energy transurethral microwave thermotherapy. J Urol 159: 1966-1972; discussion 1972-1973
310. Keoghane SR, Lawrence KC, Jenkinson CP et al. (1996) The Oxford Laser Prostate Trial: sensitivity to change of three measures of outcome. Urology 47: 43-47
311. Keoghane SR, Sullivan ME et al. (1999) A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate with a 1-year follow-up. BJU Int. 84/6: 750
312. Kinn AC, Helmy-Dhejne C et al. (1998) Sexual function one year after transurethral prostatic resection. Patients' own assessments. Scand J Urol Nephrol 32/1: 33-35
313. Kirby RS, Williams G, Witherow R, Milroy EJ, Philp T (1993) The prostatron transurethral microwave device in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia. Br J Urol 72: 190-194
314. Kirby RS (1995) Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 45/5: 775
315. Koshiba K, Egawa S, Ohori M et al. (1995) Does transurethral resection of the prostate pose a risk to life? 22-year outcome. J Urol 153: 1506-1509
316. Kunelius P, Hakkinen J et al. (1998) Sexual functions in patients with benign prostatic hyperplasia before and after transurethral resection of the prostate. Urol Res 26/1: 7-9
317. Kupeli S, Baltaci S et al. (1998) A prospective randomized study of transurethral resection of the prostate and transurethral vaporization of the prostate as a therapeutic alternative in the management of men with BPH. Eur Urol 34/1: 15-18
318. Larson TR, Bostwick DG, Corica A (1996) Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology 47: 463-469
319. Leach GE, Trockman B, Wong A et al. (1996) Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol 155/4: 1256-1259
320. Leyh H, Hartung R et al. (1999) Coagulating intermittent cutting. Improved high-frequency surgery in transurethral prostatectomy. Urologe (A) 38/6: 592-598
321. Luttwak Z, Lask D, Abarbanel J et al. (1997) Transvesical prostatectomy in elderly patients. J Urol 157: 2210-2211
322. Madersbacher S, Marberger M (1999) Is transurethral resection of the prostate still justified? BJU Int. 83/3: 227-237
323. Madsen FA, Bruskewitz RC (1995) Transurethral incision of the prostate. Urol Clin North Am 22: 369-373
324. Marshall VR (2000) In-hospital mortality after transurethral prostatectomy in Victorian hospitals. Aust N Z J Surg 70/5: 321
325. Marteinsson VT, Due J (1994) Transurethral microwave thermotherapy for uncomplicated benign prostatic hyperplasia. A prospective study with emphasis on symptomatic improvement and complications. Scand J Urol Nephrol 28: 83-89
326. Matani Y, Mottrie AM, Stöckle M et al. (1996) Transurethral prostatectomy: A long-term follow-up study of 166 patients over 80 years of age. Eur Urol 30: 414-417
327. McCullough DL (1997) Editorial: benign prostatic hyperplasia - Which tests predict good outcomes following transurethral resection of the prostate and the role of laser vaporization in treatment. J Urol 157: 1313-1314
328. Mebust WK (1994) Selection of the surgical procedure for management of benign prostatic hyperplasia. Progr Clin Biol Res 386: 369-384
329. Meseguer Barros CM, Fidalgo Garcia ML et al. (2000) Cost-effectiveness analysis of the treatment of moderate benign prostatic hyperplasia. Aten Primaria 25/8: 546-551
330. Millan Rodriguez F, Rosales Bordes A et al. (1999) Clinical trial of the effect of urethral catheter on the etiology of urethral stenosis following transurethral resection of the prostate. Arch Esp Urol 52/9: 967-972
331. Morita T, Matsuki K et al. (1999) Transurethral resection of benign prostatic hyperplasia using a vaporizing resecting loop, UROloop. Hinyokika Kiyo 45/2: 91-94
332. Mottet N, Anidjar M et al. (1999) Randomized comparison of transurethral electroresection and holmium: YAG laser vaporization for symptomatic benign prostatic hyperplasia. J Endourol 13/2: 127-130
333. Muschter R, Hofstetter A (2000) Treatment of benign prostatic hyperplasia syndrome. 2: Interventional therapy. MMW Fortschr Med 142 (3 Suppl): 161-169
334. Narayan P, Tewari A, Aboseif S, Evans C (1995) A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia. J Urol 154: 2083-2088
335. Narayan P, Starling J (1998) Minimally invasive therapies for the treatment of symptomatic benign prostatic hyperplasia: the University of Florida experience. J Clin Laser Med Surg 16/1: 29-32
336. Neal DE (1994) Evaluation and results of treatment for prostatism. Urol Res 22: 61-66
337. Netto NR Jr., De Lima ML et al. (1999) Is transurethral vaporization a remake of transurethral resection of the prostate? J Endourol 13/8: 591-594
338. Oesterling JE, Defalco AJ, Kaplan SA et al. (1994) The North American experience with the uroLume endoprosthesis as treatment for benign prostatic hyperplasia: long-term results. Urology 44: 353-362
339. Ogden CW, Reddy P, Johnson H, Ramsay JW, Carter SS (1993) Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 341: 14-17
340. Okada T, Terai A et al. (1998) Transurethral electrovaporization of the prostate: preliminary clinical results with pressure-flow analysis. Int J Urol 5/1: 55-59; discussion 59-60
341. Patel A, Fuchs GJ et al. (1999) Completeness and efficiency of prostate tissue removal: loop resection compared with a new operative technique of transurethral electrovaporization. BJU Int 84/1: 43-49
342. Patel A, Fuchs GJ et al. (2000) Transurethral electrovaporization and vapour-resection of the prostate: an appraisal of possible electrosurgical alternatives to regular loop resection. BJU Int 85/2: 202-210
343. Perera ND, Hill JT (1998) Erectile and ejaculatory failure after transurethral prostatectomy. Ceylon Med J 43/2: 74-77
344. Perlmutter AP, Schulsinger DA (1998) The "Wedge" resection device for electrosurgical transurethral prostatectomy. J Endourol 12/1: 75-79
345. Perlmutter AP, Vallanden G (1999) Thick loop transurethral resection of the prostate. Eur Urol 35/2: 161-165
346. Puri R, Smaling A et al. (1999) How is follow-up after transurethral prostatectomy best performed? BJU Int 84/7: 795-798
347. Ramsey EW, Dahlstrand C (2000) Durability of results obtained with transurethral microwave thermotherapy in the treatment of men with symptomatic benign prostatic hyperplasia. J Endourol 14: 671-675
348. Rasor JS, Zlotta AR, Edwards SD, Schulman CC (1993) Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia. Eur Urol 24: 411-414
349. Reynard JM, RJ Shearer RJ (1999) Failure to void after transurethral resection of the prostate and mode of presentation. Urology 53/2: 336-339
350. Riehmann RC, Knes JM, Heisey D, Madsen PO, Bruskewitz RC (1995) Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 45: 768-775
351. Rodrigues Netto N Jr., Claro JdA, Cortado PL (1994) Ejaculatory dysfunction after transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. J Endourol 8: 217-219
352. Roehrborn CG (1996) Editorial: fine-tuning the indication for prostatectomy. J Urol 155: 203-205
353. Roehrborn CG, Preminger G, Newhall P et al. (1998) Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. Urology 51: 19-28
354. Ronzoni G, M. De Vecchis (1998) Preservation of anterograde ejaculation after transurethral resection of both the prostate and bladder neck. Br J Urol 81/6: 830-833
355. Roos NP, Wennberg JE, Malenka DJ et al. (1989) Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 320: 1120-1124
356. Rosario DJ, Woo H, Potts KL et al. (1997) Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 80: 579-586
357. Schatzl G, Madersbacher S et al. (2000) Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol 37/6: 695-701
358. Schulman CC, Zlotta AR (1995) Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 45: 28-33
359. Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA (1994) Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. J Urol 152: 935-937
360. Sengör F, Köse O, Yücebas E et al. (1996) A comparative study of laser ablation and transurethral electroresection for benign prostatic hyperplasia: results of a 6-months follow-up. Br J Urol 78: 398-400
361. Sheu MH, Chiang H et al. (2000) Transurethral resection of the prostate-related changes in the prostate gland: correlation of MRI and histopathology. J Comput Assist Tomogr 24/4: 596-599
362. Sirls T, Ganabathi K, Zimmern PE (1994) Transurethral incision of the prostate: an objective and subjective evaluation of long term efficacy. J Urol (Paris) 100/5: 249-256
363. Soderdahl DW, Knight RW, Hansberry KL (1996) Erectile dysfunction following transurethral resection of the prostate. J Urol 156: 1354-1356
364. Sparwasser C, Riehmann M, Knes J, Madsen PO (1995) Langzeitergebnisse der transurethralen Prostatainzision (TUIP) und transurethralen Prostataresektion (TURP). Eine prospektiv randomisierte Studie. Urologe (A)34: 153-157
365. Steele GS, Sleep DJ (1997) Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol 158: 1834-188
366. Talic RF (1999) Transurethral electrovaporization-resection of the prostate using the "wing" cutting electrode: preliminary results of safety and efficacy in the treatment of men with prostatic outflow obstruction. Urology 53/1: 106-110
367. Talic RF, Al Rikabi AC (2000) Transurethral vaporization-resection of the prostate versus standard transurethral prostatectomy: comparative changes in histopathological features of the resected specimens. Eur Urol 37/3: 301-305
368. Talic RF, El Tiraifi A et al. (2000) Prospective randomized study of transurethral vaporization resection of the prostate using the thick loop and standard transurethral prostatectomy. Urology 55/6: 886-890
369. Terai A, Arai Y, Onishi H et al. (1995) Transurethral microwave thermotherapy for benign prostatic hyperplasia: clinical results after a 1-year follow-up. Int J Urol 2: 24-28
370. Thorpe AC, Cleary R, Coles J et al. (1994) Deaths and complications following prostatectomy in 1400 men in the Northern Region of England. Br J Urol 74: 559-565
371. Tsai YS, Lin JS, Tong YC et al. (2001) Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: Long-term durability with prostcare. Eur Urol 39: 688-694
372. Tscholl R, Largo M, Poppinghaus E, Recker F, Subotic B (1995) Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative snap gauge tests. J Urol 153: 1491-1493
373. Tubaro A, Paradiso Galatioto G, Trucchi A et al. (1993) Transurethral microwave thermotherapy in the treatment of symptomatic benign prostatic hyperplasia. Eur Urol 23: 285-291
374. Tubaro A, Carter SS, de la Rosette JJ (1995) The prediction of clinical outcome from transurethral microwave thermotherapy by pressure-flow analysis: a European multicenter study. J Urol 153: 1526-1530
375. Uchida T, Ohori M et al. (1999) Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 53/1: 98-105
376. Van Cauwelaert RR, Castillo OC, Aquirre CA, Azocar GH, Medina FI (1993) Transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia: preliminary experience. Eur Urol 23: 282-284
377. van Swol CF, van Vliet RJ et al. (1999) Electrovaporization as a treatment modality for transurethral resection of the prostate: influence of generator type. Urology 53/2: 317-321
378. Walden M, Acosta S et al. (1998) A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: two-year follow-up. Scand J Urol Nephrol 32/3: 204-210
379. Winters JC, Appell RA et al. (1998) Urodynamic findings in postprostatectomy incontinence. Neurourol Urodyn 17/5: 493-498
380. Yang Q, Abrams P et al. (1999) Transurethral resection or incision of the prostate and other therapies: a survey of treatments for benign prostatic obstruction in the UK. BJU Int. 84/6: 640-645
381. Zhou Z, Wang Z et al. (1998) Transurethral prostate vaporization using an oval electrode in 82 cases of benign prostatic hyperplasia. Chin Med J (Engl) 111/1: 52-55
382. Zorn BH, Bauer JJ et al. (1999) Randomized trial of safety and efficacy of transurethral resection of the prostate using contact laser versus electrocautery. Tech Urol 5/4: 198-201
383. Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe (B) 40: 437-443
384. Becker H, Ebeling L (1988) Konservative Therapie der benignen Prostatahyperplasie (BPH) mit Cernilton. Urologe (B) 28: 301-306
385. Berges RR, Windeler J, Trampisch H et al. (1995) Randomised, placebo-controlled, double blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529-1532
386. Buck AC, Cox R, Rees RWM et al. (1990) Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen ectract Cernilton. Br J Urol 66: 398-404
387. (r)) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1.089 patients. Prostate 29: 231-240
388. Debruyne F (2001) Phytotherapy (LSESR) vs α-blocker for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: A randomized comparative study. J Urol 165/5: 381-382 (Abstr 1562)
389. Klippel KF, Hiltl D-M, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 80: 427-432
390. Kuznetsow DD, Gerber GS, Burstein JD (2001) Randomized, double blind, placebo-controlled study of saw palmetto in men with lower urinary tract symtoms (LUTS). J Urol 165/5: 263 (Abstr 1084)
391. Sökeland J, Albrecht J (1997) Kombination aus Sabalund Urticaextrakt mit Finasterid bei BPH (Stadiuml bis II nach Alken). Urologe (A) 36: 327-333